Immune reconstitution inflammatory syndrome: A reappraisal

Clinical Infectious Diseases

Volumn 48, Issue 1, 2009, Pages 101-107

  French, Martyn A ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN SPECIFICITY; CORTICOSTEROID THERAPY; CRYPTOCOCCUS NEOFORMANS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFLAMMATION; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ACQUIRED IMMUNE DEFICIENCY SYNDROME; IMMUNOLOGY;

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MYCOBACTERIUM TUBERCULOSIS;

EID: 57749107807     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/595006     Document Type: Review

References (67)

1. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:16-21.
2. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213-27.
3. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107-15.
4. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-27.
5. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483-97.
6. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005;23:5224-8.
7. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1-13.
8. + lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol 2004; 108:17-23.
9. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709-12.
10. Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37:1574-6.
11. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-41.
12. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11:1282-9.
13. Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:1049-52.
14. Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F; French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043-9.
15. Lawn SD, Bekker LG, Myer L, Orrell C,Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050-2.
16. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-701.
17. Schrier RD, Song MK, Smith IL, et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina 2006; 26:165-9.
18. Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005; 11(Suppl 3):16-22.
19. Mutimer HP, Akatsuka Y, Manley T, et al. Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response. J Infect Dis 2002; 186:701-5.
20. Breton G, Adle-Biassette H, Therby A, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 2006; 20:119-21.
21. Blanche P, Gombert B, Rivoal O, Abad S, Salmon D, Brezin A. Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS. Clin Infect Dis 2002; 34:1279-80.
22. Batista MD, Porro AM, Maeda SM, et al. Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS. Clin Infect Dis 2008; 46:e56-60.
23. Couppié P, Abel S, Voinchet H, et al. Immune reconstitution inflammatory syndrome associated with HIV and leprosy. Arch Dermatol 2004; 140:997-1000.
24. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20:F1-7.
25. Elliott JH, Khol V, Sarun S, et al. Investigation of the pathogenesis and diagnosis of tuberculosis-associatedimmunereconstitution inflammatory syndrome and antiretroviral therapy-associated tuberculosis using skin testing and a whole blood interferon-γ release assay [abstract WEPE0201]. In: Program and abstracts of the XVII International AIDS Conference (Mexico City). 2008.
26. Tan DB, Yong YK, Tan HY, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med 2008; 9:307-16.
27. Puthanakit T, Oberdorfer P, Punjaisee S, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41:1049-52.
28. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS): case definitions for adults in resource-limited settings. Lancet Infect Dis 2008; 8:516-23.
29. + T cell subsets contribute to the human antimycobacterial immune response. J Immunol 2008; 180:1962-70.
30. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 2007; 51:1139-47.
31. Tamburini J, Grimaldi D, Chiche JD, Bricaire F, Bossi P. Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients. AIDS 2007; 21:1980-3.
32. Crane M, Oliver B, Matthews G, et al. Immunopathogenesis of hepatic flares in HIV-hepatitis B virus (HBV) coinfected individuals following initiation of HBV-active antiretroviral therapy. J Infect Dis (in press).
33. Lim A, Tan D, Price P, et al. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS 2007; 21:1525-34.
34. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46:456-62.
35. Miralles P, Berenguer J, Lacruz C, et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 2001; 15:1900-2.
36. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9(Suppl 1):73-80.
37. + T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J Immunol 2000; 165:1692-704.
38. Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS 2008; 3:438-45.
39. Clark BM, Krueger RG, Price P, French MA. Compartmentalization of the immune response in varicella zoster virus immune restoration disease causing transverse myelitis. AIDS 2004; 18:1218-21.
40. Trevenzoli M, Cattelan AM, Rea F, et al. Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era. J Infect 2002; 45:173-9.
41. Giudici B, Vaz B, Bossolasco S, et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000; 30:95-9.
42. Lawn SD, French MA. Immune reconstitution disease: recent developments and implications for antiretroviral treatment in resource-limited settings. Curr Opin HIV AIDS 2007; 2:339-45.
43. Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006; 10:946-53.
44. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601-10.
45. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177:680-5.
46. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-24. (erratum: Lancet 2006; 367:1902).
47. Ortega-Larrocea G, Espinosa E, Reyes-Terán G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. AIDS 2005; 19:735-8.
48. Meintjes G, Lynen L. Prevention and treatment of the immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS 2008; 3:468-76.
49. Crum NF, Ganesan A, Johns ST, Wallace MR. Graves disease: an increasingly recognized immune reconstitution syndrome. AIDS 2006; 20:466-9.
50. Knysz B, Bolanowski M, Klimczak M, Gladysz A, Zwolinska K. Graves' disease as an immune reconstitution syndrome in an HIV-1-positive patient commencing effective antiretroviral therapy: case report and literature review. Viral Immunol 2006; 19:102-7.
51. Vos F, Pieters G, Keuter M, van der Ven A. Graves' disease during immune reconstitution in HIV-infected patients treated with HAART. Scand J Infect Dis 2006; 38:124-6.
52. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006; 6:1084-5.
53. Loh Y, Oyama Y, Statkute L, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007; 109:2643-548.
54. Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab,mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 2007; 92:1029-36.
55. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008; 255:231-8.
56. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001; 344:655-64.
57. French MA, Lewin SR, Dykstra C, Krueger R, Price P, Leedman PJ. Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Res Hum Retrovir 2004; 20:157-62.
58. Kavvoura FK, Akamizu T, Awata T, et al. Cytotoxic T-lymphocyte associated antigen gene 4 polymorphisms and autoimmune thyroid disease: a meta-analysis. J Clin Endocrinol Metab 2007; 92:3162-70
59. Saverino D, Brizzolara R, Simone R, et al. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007; 123:190-8.
60. Stone SF, Price P, French MA. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy. HIV Med 2005; 6:278-83.
61. Haramati LB, Lee G, Singh A, Molina PL, White CS. Newly diagnosed pulmonary sarcoidosis in HIV-infected patients. Radiology 2001; 218:242-6.
62. Foulon G, Wislez M, Naccache JM, et al. Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:418-25.
63. Thachil J, Jadhav V, Gautam M, et al. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution. Br J Haematol 2007; 138:559-60.
64. Bhagat R, Rizzieri DA, Vredenburgh JJ, Chao NJ, Folz RJ. Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence? Chest 2004; 126:642-4.
65. Bilu D, Mamelak AJ, Nguyen RH, et al. Clinical and epidemiologic characterization of photosensitivity in HIV-positive individuals. Photodermatol Photoimmunol Photomed 2004; 20:175-83.
66. Goldberg HJ, Fiedler D, Webb A, Jagirdar J, Hoyumpa AM, Peters J. Sarcoidosis after treatment with interferon-a: a case series and review of the literature. Respir Med 2006; 100:2063-8.
67. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357:2153-65.